Cardiovascular Manifestations in Newly Diagnosed Hyperthyroid Patients and their Outcome with Anti-Thyroid Treatment.
To evaluate the incidence of cardiovascular abnormalities in newly identified hyperthyroid patients and their outcome with anti-thyroid therapy. A total of 96 patients who were newly diagnosed to have hyperthyroid disease were screened and out of them, 40 patients who presented with cardiovascular symptoms and sign were included in study (30 females, 10 males). Hyperthyroid patients were re-evaluated after antithyroid therapy. Findings in patients were compared at presentation, and after 3 month of treatment. All had undergone a structured cardiovascular history and examination, including measurements of blood pressure (BP) and pulse rate. All had resting 12-lead electrocardiogram and 2D ECHO. Cardiovascular symptoms and signs, as well as abnormal hemodynamic and dysrhythmias, especially supraventricular, were frequent among patients with hyperthyroidism. Palpitation and atrial fibrillation (AF) were more recurrent in overt hyperthyroid subjects than those with subclinical hyperthyroidism and remained more prevalent after 3 month of antithyroid treatment in that subject who had persistently high serum T3 and T4 level. Cardiovascular abnormalities are one of the most common presentations in patients with hyperthyroidism and they respond very well to treatment before the structural changes occur in the cardiovascular system.